HOLX vs. BDX, EW, IDXX, RMD, DXCM, STE, PODD, BAX, GMED, and MASI
Should you be buying Hologic stock or one of its competitors? The main competitors of Hologic include Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), IDEXX Laboratories (IDXX), ResMed (RMD), DexCom (DXCM), STERIS (STE), Insulet (PODD), Baxter International (BAX), Globus Medical (GMED), and Masimo (MASI). These companies are all part of the "health care equipment" industry.
Hologic vs.
Hologic (NASDAQ:HOLX) and Becton, Dickinson and Company (NYSE:BDX) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, community ranking, valuation, profitability, risk, earnings, institutional ownership and media sentiment.
Hologic has a beta of 0.97, suggesting that its stock price is 3% less volatile than the S&P 500. Comparatively, Becton, Dickinson and Company has a beta of 0.39, suggesting that its stock price is 61% less volatile than the S&P 500.
Becton, Dickinson and Company has higher revenue and earnings than Hologic. Hologic is trading at a lower price-to-earnings ratio than Becton, Dickinson and Company, indicating that it is currently the more affordable of the two stocks.
In the previous week, Becton, Dickinson and Company had 5 more articles in the media than Hologic. MarketBeat recorded 17 mentions for Becton, Dickinson and Company and 12 mentions for Hologic. Hologic's average media sentiment score of 0.69 beat Becton, Dickinson and Company's score of 0.67 indicating that Hologic is being referred to more favorably in the media.
Hologic presently has a consensus price target of $89.50, indicating a potential upside of 24.83%. Becton, Dickinson and Company has a consensus price target of $283.50, indicating a potential upside of 21.34%. Given Hologic's higher possible upside, equities analysts clearly believe Hologic is more favorable than Becton, Dickinson and Company.
94.7% of Hologic shares are owned by institutional investors. Comparatively, 87.0% of Becton, Dickinson and Company shares are owned by institutional investors. 1.8% of Hologic shares are owned by insiders. Comparatively, 0.4% of Becton, Dickinson and Company shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Hologic has a net margin of 19.59% compared to Becton, Dickinson and Company's net margin of 8.55%. Hologic's return on equity of 19.79% beat Becton, Dickinson and Company's return on equity.
Hologic received 279 more outperform votes than Becton, Dickinson and Company when rated by MarketBeat users. Likewise, 69.63% of users gave Hologic an outperform vote while only 62.32% of users gave Becton, Dickinson and Company an outperform vote.
Summary
Hologic beats Becton, Dickinson and Company on 13 of the 19 factors compared between the two stocks.
Get Hologic News Delivered to You Automatically
Sign up to receive the latest news and ratings for HOLX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
This page (NASDAQ:HOLX) was last updated on 1/13/2025 by MarketBeat.com Staff
Free HOLX Stock Alerts